The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review

Background: Natural resources provide more efficient and safer alternatives in managing diabetes compare to the synthetic oral anti diabetes (OAD). The plants not only have hypoglycemic effect, but also prevent its complications; in which no synthetic drugs provide of both properties. Among antidiab...

Full description

Bibliographic Details
Main Authors: Sukardiman, Martha Ervina
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844020303819
_version_ 1818791391655886848
author Sukardiman
Martha Ervina
author_facet Sukardiman
Martha Ervina
author_sort Sukardiman
collection DOAJ
description Background: Natural resources provide more efficient and safer alternatives in managing diabetes compare to the synthetic oral anti diabetes (OAD). The plants not only have hypoglycemic effect, but also prevent its complications; in which no synthetic drugs provide of both properties. Among antidiabetes plants, mahogany seed (Swietenia macrophylla) has been used as traditional medicine in Indonesia and India, though most popular utilized as timber wood. Methods: The present study was performed of chemotaxonomic approach to review its phytochemical and anti-diabetic properties of Swietenia mahagoni (L.) Jacq seed/bark/leaves. The qualitative systematic review (SR) was carried out by analysing indexed journals and peer reviewed of Swietenia and Swietenia spp from Scopus, PubMed, Medline, Google Scholar, and Research Gate. Data selection criteria are accordance to botany, phytochemistry, in vitro, in vivo, and clinical test of related subject. The keywords used for the search in the databases were Swietenia, Swietenia mahagony, diabetes, and diabetes plants. Results: Swietenia mahagoni (L.) Jacq. extracts have shown in vitro, in vivo and limited clinically test of its anti-diabetic properties. Ethanolic/methanolic/aqueous/petroleum/n-hexane extracts of mahagonis's seed/bark or leaves have anti-diabetic activities comparable to the synthetic drug and observed no to relatively mild toxic effect. The hypoglycemic mechanism suggested via reducing blood glucose level, restoring liver and β-cells islet function (might) blocking epinephrine function, inhibiting of α-amylase and β-glucosidase, antioxidant and antihiperlipidemia. Phytochemical compounds of S. mahagoni consist of the phenolics (flavonoids (swietemacrophyllanin, catechins and epichatechins) and tannins), triterpenoids and tetranortriterpenoids (limonoids: mahonin, secomahoganin, swietmanins, swiemahogins, swietenine and swietenolide), saponins and alkaloids which are known as anti-diabetic bioactive principles. Conclusion: S. mahagoni was potentially used and developed as an antidiabetes source. To use it as an antidiabetic further, more extensive clinical trials and biomarkers of active compounds determination are needed.
first_indexed 2024-12-18T15:10:37Z
format Article
id doaj.art-eabc72bfd7694f7facc2d60e88833a28
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-12-18T15:10:37Z
publishDate 2020-03-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-eabc72bfd7694f7facc2d60e88833a282022-12-21T21:03:40ZengElsevierHeliyon2405-84402020-03-0163e03536The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review Sukardiman0Martha Ervina1Department of Pharmacognosy and Phytochemistry, Universitas Airlangga, Indonesia; Corresponding author.Doctoral Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia; Faculty of Pharmacy Widya Mandala Catholic University, Surabaya, IndonesiaBackground: Natural resources provide more efficient and safer alternatives in managing diabetes compare to the synthetic oral anti diabetes (OAD). The plants not only have hypoglycemic effect, but also prevent its complications; in which no synthetic drugs provide of both properties. Among antidiabetes plants, mahogany seed (Swietenia macrophylla) has been used as traditional medicine in Indonesia and India, though most popular utilized as timber wood. Methods: The present study was performed of chemotaxonomic approach to review its phytochemical and anti-diabetic properties of Swietenia mahagoni (L.) Jacq seed/bark/leaves. The qualitative systematic review (SR) was carried out by analysing indexed journals and peer reviewed of Swietenia and Swietenia spp from Scopus, PubMed, Medline, Google Scholar, and Research Gate. Data selection criteria are accordance to botany, phytochemistry, in vitro, in vivo, and clinical test of related subject. The keywords used for the search in the databases were Swietenia, Swietenia mahagony, diabetes, and diabetes plants. Results: Swietenia mahagoni (L.) Jacq. extracts have shown in vitro, in vivo and limited clinically test of its anti-diabetic properties. Ethanolic/methanolic/aqueous/petroleum/n-hexane extracts of mahagonis's seed/bark or leaves have anti-diabetic activities comparable to the synthetic drug and observed no to relatively mild toxic effect. The hypoglycemic mechanism suggested via reducing blood glucose level, restoring liver and β-cells islet function (might) blocking epinephrine function, inhibiting of α-amylase and β-glucosidase, antioxidant and antihiperlipidemia. Phytochemical compounds of S. mahagoni consist of the phenolics (flavonoids (swietemacrophyllanin, catechins and epichatechins) and tannins), triterpenoids and tetranortriterpenoids (limonoids: mahonin, secomahoganin, swietmanins, swiemahogins, swietenine and swietenolide), saponins and alkaloids which are known as anti-diabetic bioactive principles. Conclusion: S. mahagoni was potentially used and developed as an antidiabetes source. To use it as an antidiabetic further, more extensive clinical trials and biomarkers of active compounds determination are needed.http://www.sciencedirect.com/science/article/pii/S2405844020303819ToxicologyDiabetesHypoglycemicMahoganyMeliaceaeSwietenia sp
spellingShingle Sukardiman
Martha Ervina
The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
Heliyon
Toxicology
Diabetes
Hypoglycemic
Mahogany
Meliaceae
Swietenia sp
title The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_full The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_fullStr The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_full_unstemmed The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_short The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_sort recent use of swietenia mahagoni l jacq as antidiabetes type 2 phytomedicine a systematic review
topic Toxicology
Diabetes
Hypoglycemic
Mahogany
Meliaceae
Swietenia sp
url http://www.sciencedirect.com/science/article/pii/S2405844020303819
work_keys_str_mv AT sukardiman therecentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview
AT marthaervina therecentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview
AT sukardiman recentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview
AT marthaervina recentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview